CN114106013A - 斑螯素和生物活性斑螯素衍生物的商业上可行的合成 - Google Patents

斑螯素和生物活性斑螯素衍生物的商业上可行的合成 Download PDF

Info

Publication number
CN114106013A
CN114106013A CN202111209225.4A CN202111209225A CN114106013A CN 114106013 A CN114106013 A CN 114106013A CN 202111209225 A CN202111209225 A CN 202111209225A CN 114106013 A CN114106013 A CN 114106013A
Authority
CN
China
Prior art keywords
compound
cantharidin
reaction
iii
triflate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111209225.4A
Other languages
English (en)
Chinese (zh)
Inventor
M.戴维森
S.R.肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verrica Pharmaceuticals Inc
Original Assignee
Verrica Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56127857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN114106013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Verrica Pharmaceuticals Inc filed Critical Verrica Pharmaceuticals Inc
Publication of CN114106013A publication Critical patent/CN114106013A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D497/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN202111209225.4A 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成 Pending CN114106013A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093396P 2014-12-17 2014-12-17
US62/093,396 2014-12-17
CN201580076312.3A CN107530322B (zh) 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580076312.3A Division CN107530322B (zh) 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成

Publications (1)

Publication Number Publication Date
CN114106013A true CN114106013A (zh) 2022-03-01

Family

ID=56127857

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111209225.4A Pending CN114106013A (zh) 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成
CN201580076312.3A Active CN107530322B (zh) 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580076312.3A Active CN107530322B (zh) 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成

Country Status (12)

Country Link
US (2) US10745413B2 (cg-RX-API-DMAC7.html)
EP (1) EP3233865A4 (cg-RX-API-DMAC7.html)
JP (4) JP6810693B2 (cg-RX-API-DMAC7.html)
KR (1) KR102528106B1 (cg-RX-API-DMAC7.html)
CN (2) CN114106013A (cg-RX-API-DMAC7.html)
AU (2) AU2015364524A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017013029B1 (cg-RX-API-DMAC7.html)
CA (1) CA2971279C (cg-RX-API-DMAC7.html)
HK (1) HK1246276A1 (cg-RX-API-DMAC7.html)
IL (2) IL252907B2 (cg-RX-API-DMAC7.html)
MX (2) MX385473B (cg-RX-API-DMAC7.html)
WO (1) WO2016100732A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027111A1 (en) 2013-08-21 2015-02-26 Verrica Pharmaceuticals, Inc. Compositions, methods and systems for the treatment of cutaneous disorders
JP6810693B2 (ja) 2014-12-17 2021-01-06 ヴェリカ ファーマシューティカルズ, インコーポレイテッドVerrica Pharmaceuticals, Inc. カンタリジンおよび生理活性カンタリジン誘導体の商業的に実現可能な合成
EP3247996A4 (en) 2015-01-20 2019-01-02 Verrica Pharmaceuticals, Inc. Quantification and preparation of pharmaceutical grade cantharidin
CN106674248B (zh) * 2016-12-17 2019-02-26 重庆市中药研究院 一种斑蝥素的合成工艺
US11147790B2 (en) 2017-06-06 2021-10-19 Verrica Pharmaceuticals Inc. Treatment of cutaneous disorders
CA3253199A1 (en) 2017-06-15 2025-10-30 Verrica Pharmaceuticals Inc. Devices and methods for the treatment of body surface disorders
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator
AU2018346414B2 (en) * 2017-10-04 2023-07-06 Verrica Pharmaceuticals, Inc. Synthesis of cantharidin
WO2019086922A1 (en) * 2017-10-31 2019-05-09 Université de Bourgogne Therapeutical compositions for use in the treatment of non- malignant conditions associated with phosphatidylinositol-3- kinase activation: overgrowth spectrum, cutaneous capillary malformations and seborrheic keratoses
CN113455515A (zh) * 2021-06-24 2021-10-01 广东省农业科学院果树研究所 斑蝥素在制备防治柑橘采后绿霉菌的农药杀菌剂的应用
KR20240012182A (ko) 2022-07-20 2024-01-29 고려대학교 산학협력단 칸타리딘을 유효성분으로 포함하는 교모세포종 예방 또는 치료용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298752A (en) * 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method
US20040152766A1 (en) * 2001-05-31 2004-08-05 Au-Yeung Steven C.F. Composition comprising demethylcantharidin in combination with platinum-containing anticancer agents and use thereof
CN1571795A (zh) * 2001-10-19 2005-01-26 伊索泰克尼卡股份有限公司 环孢菌素类似物的合成
CN101161654A (zh) * 2007-08-16 2008-04-16 广东药学院 一种抗肿瘤活性斑蛰素衍生物及其制备方法
CN103923095A (zh) * 2014-04-23 2014-07-16 遵义医学院 一种去甲基斑蝥素酸钙

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4739621Y1 (cg-RX-API-DMAC7.html) 1968-04-18 1972-11-30
US4148887A (en) 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JP3117502B2 (ja) 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
JPH05255367A (ja) * 1992-02-28 1993-10-05 Jitsuei O カンタリジン誘導体組成物の製造法及びそれを含む抗ウイルス剤
US5445462A (en) 1993-08-03 1995-08-29 Medi-Flex Hospital Products, Inc. Liquid applicator
WO1995005156A1 (en) 1993-08-17 1995-02-23 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
US5590780A (en) 1995-06-22 1997-01-07 Wheaton Holding, Inc. Unit dose assembly
FR2754175B1 (fr) 1996-10-07 1999-07-02 Oreal Utilisation d'un organopolysiloxane de nature elastomerique associe a une phase organique dans un produit de demaquillage des ongles
US6030633A (en) 1998-05-18 2000-02-29 West Agro, Inc. Film-forming compositions for protecting animal skin
JPH11335303A (ja) 1998-05-26 1999-12-07 Lion Corp 苦味増強方法及び皮膚外用剤
US6337076B1 (en) 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US20030072814A1 (en) 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6899897B2 (en) 2001-06-18 2005-05-31 Jaleva, Inc. Gum resin as a carrier for topical application of pharmacologically active agents
US6673031B2 (en) 2001-09-25 2004-01-06 Phillip Mark Liquid applicator
JP2004059446A (ja) * 2002-07-25 2004-02-26 Mitsui Chemicals Inc 脂環式化合物及びその製造方法
RU2326893C2 (ru) 2003-04-16 2008-06-20 Кориум Интернэшнл Ковалентное и нековалентное сшивание гидрофильных полимеров и адгезивные композиции, полученные с ними
US20070111954A1 (en) 2003-07-23 2007-05-17 Cuticeuticals, Inc. Apparatus and method of wart treatment
US20050019418A1 (en) 2003-07-23 2005-01-27 Crutchfield Charles E. Wart treatment
JP2005187330A (ja) 2003-12-24 2005-07-14 Lion Corp 歯牙貼布用製品及びゲル組成物の選定方法
FR2865360B1 (fr) 2004-01-22 2006-05-26 Oreal Applicateur comportant un element d'application solidaire, lors de l'utilisation, d'un recipient contenant un produit a appliquer
FR2872704B1 (fr) * 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20050111900A1 (en) 2004-11-30 2005-05-26 Francesca Fazzolari Ampoule and method of use
FR2885779B1 (fr) 2005-05-23 2007-08-10 Oreal Dispositif de conditionnement et d'application d'un produit cosmetique ou dermatologique
US20070187437A1 (en) 2006-02-10 2007-08-16 Nordson Corporation Dispensing tip for liquid dispensing systems and method of making the same
JP5132071B2 (ja) 2006-03-31 2013-01-30 小林製薬株式会社 皮膚外用剤
DE102006034272A1 (de) 2006-07-18 2008-01-24 Aesculap Ag & Co. Kg Flüssigkeitsspender in der Medizin in Form einer Handhabe sowie dessen Verwendung
CN100465176C (zh) 2006-08-18 2009-03-04 芜湖天远科技开发有限责任公司 一种提取斑蝥素的方法
US20080146674A1 (en) 2006-12-15 2008-06-19 Rosenberg E William Use of gentian violet in treatment of atopic dermatitis
US8518076B2 (en) 2007-01-08 2013-08-27 Advanced Medical Solutions (Plymouth) Limited Surgical adhesive applicator
US8262608B2 (en) 2007-01-25 2012-09-11 Hyperbranch Medical Technology, Inc. Applicators for multiple component formulations and the like, and methods of use thereof
CN101036774B (zh) 2007-04-17 2010-12-29 贵州益佰制药股份有限公司 一种复方斑蝥口服制剂的检测方法
CN101108853B (zh) 2007-07-27 2010-05-26 贵州大学 斑蝥素分离纯化方法
DE102007046600A1 (de) 2007-09-27 2009-04-02 Linhardt Metallwarenfabrik Gmbh & Co Kg Verfahren zum Applizieren eines flüssigen, medizinischen Behandlungsmediums auf einen zu behandelden Bereich sowie Medizinprodukt
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
JP5396125B2 (ja) 2009-03-30 2014-01-22 有限会社日本健康科学研究センター 被膜形成型製剤
EP2485720B1 (en) 2009-10-08 2018-08-22 Bayer Consumer Care AG Low ether composition and delivery apparatus
US20120016320A1 (en) 2010-07-13 2012-01-19 Lin Michael T Method and Device for Liquid Delivery
US20120148520A1 (en) 2010-12-10 2012-06-14 Michael Strobel Organic Iodine Complex Durable Barrier With Antimicrobial Preparations
FR2972928B1 (fr) 2011-03-25 2013-11-29 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
US20120312709A1 (en) 2011-04-12 2012-12-13 Velcera, Inc. Device for storing and dispensing a medicament, and packaging for containing the same
CN102146086B (zh) 2011-04-12 2012-03-07 贵州金桥药业有限公司 一种斑蝥酸钠的制备方法
US9486829B2 (en) 2011-06-04 2016-11-08 Optmed, Inc. Applicator
CN102268006B (zh) 2011-06-15 2013-08-14 北京联合大学生物化学工程学院 一种复合酶提取斑蝥素的方法
US8871801B2 (en) 2011-08-01 2014-10-28 Jacob LEVITT Method of treating acquired perforating dermatosis with cantharidin
CN202920809U (zh) 2012-09-27 2013-05-08 合肥诚者成医药科技有限公司 一种治疗尖锐湿疣的软膏
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
WO2015027111A1 (en) 2013-08-21 2015-02-26 Verrica Pharmaceuticals, Inc. Compositions, methods and systems for the treatment of cutaneous disorders
US9994584B2 (en) 2014-10-15 2018-06-12 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
JP6810693B2 (ja) 2014-12-17 2021-01-06 ヴェリカ ファーマシューティカルズ, インコーポレイテッドVerrica Pharmaceuticals, Inc. カンタリジンおよび生理活性カンタリジン誘導体の商業的に実現可能な合成
EP3247996A4 (en) 2015-01-20 2019-01-02 Verrica Pharmaceuticals, Inc. Quantification and preparation of pharmaceutical grade cantharidin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298752A (en) * 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method
US20040152766A1 (en) * 2001-05-31 2004-08-05 Au-Yeung Steven C.F. Composition comprising demethylcantharidin in combination with platinum-containing anticancer agents and use thereof
CN1571795A (zh) * 2001-10-19 2005-01-26 伊索泰克尼卡股份有限公司 环孢菌素类似物的合成
CN101161654A (zh) * 2007-08-16 2008-04-16 广东药学院 一种抗肿瘤活性斑蛰素衍生物及其制备方法
CN103923095A (zh) * 2014-04-23 2014-07-16 遵义医学院 一种去甲基斑蝥素酸钙

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PAUL A. GRIECO等: "Dramatic Rate Accelerations of Diels-Alder Reactions in 5 M Lithium Perchlorate-Diethyl Ether: The Cantharidin Problem Reexamined", 《J. AM. CHEM. SOC.》, vol. 112, pages 4595 *
WILLIAM G. DAUBEN等: "Organic Reactions at High Pressure. The Preparative Scale Synthesis of Cantharidin", 《J. ORG. CHEM.》, vol. 50, no. 14, pages 2576, XP055456344, DOI: 10.1021/jo00214a034 *
戴素俊等: "斑螯素对STZ诱导的1型糖尿病小鼠胰岛功能和形态的影响", 南京医科大学学报(自然科学版), vol. 27, no. 05, pages 441 - 443 *

Also Published As

Publication number Publication date
IL274968A (en) 2020-07-30
US10745413B2 (en) 2020-08-18
US20190002474A1 (en) 2019-01-03
AU2020244554B2 (en) 2022-10-20
IL252907B2 (en) 2023-08-01
JP2024037931A (ja) 2024-03-19
CA2971279C (en) 2023-09-19
MX385473B (es) 2025-03-18
IL252907A0 (en) 2017-08-31
JP2018500336A (ja) 2018-01-11
JP2021073173A (ja) 2021-05-13
EP3233865A4 (en) 2018-12-05
JP7777726B2 (ja) 2025-12-01
JP2026040458A (ja) 2026-03-09
CA2971279A1 (en) 2016-06-23
WO2016100732A3 (en) 2016-09-09
US20210070771A1 (en) 2021-03-11
CN107530322B (zh) 2021-10-15
MX2017008097A (es) 2018-01-09
HK1246276A1 (zh) 2018-09-07
KR20170117027A (ko) 2017-10-20
AU2020244554A1 (en) 2020-10-29
BR112017013029A2 (pt) 2018-01-09
KR102528106B1 (ko) 2023-05-03
WO2016100732A2 (en) 2016-06-23
BR112017013029B1 (pt) 2022-12-06
CN107530322A (zh) 2018-01-02
IL252907B (en) 2020-06-30
MX2021010078A (es) 2021-09-21
AU2015364524A1 (en) 2017-07-13
EP3233865A2 (en) 2017-10-25
JP6810693B2 (ja) 2021-01-06

Similar Documents

Publication Publication Date Title
CN107530322B (zh) 斑螯素和生物活性斑螯素衍生物的商业上可行的合成
US12221452B2 (en) Synthesis of cantharidin
Ding et al. Total synthesis of (−)-dactylolide and formal synthesis of (−)-zampanolide via target oriented β-C-glycoside formation
Forcher et al. A stereoselective access to a ferrocene-based planar chiral triazolium salt
Guanti et al. Simplified dynemicin analogues: diastereoselective synthesis and evaluation of their activity against plasmid DNA
Wang et al. Enantioselective Michael addition of cyclic ketones to nitroolefins catalyzed by a novel fluorine-insertion organocatalyst
Ali et al. The stereochemistry of 1, 3-dipolar cycloaddition of internally H-bonded chiral methylenenitrones
CN110684044B (zh) 一种制备Tubulysin关键片段Tuv的方法
CN117263801B (zh) 一种光催化lmct制备二氟甲基类化合物的方法
Marty et al. Diastereoselective synthesis of (1S, 2S, 3R, 6S) 3-chloro-3-methyl-6-isopropenyl-1, 2-cyclohexanediol via Prins reaction induced by Zinc and trimethylsilyl chloride
Hochstetler Hydroboration of dihydrothujopsene
Philipova et al. (−)-Fenchone derived epoxy alcohols—preparation and configuration
Shrestha Novel Methodologies to Achieve High Regio-and Site-Selectivity in Complex Molecule Synthesis via Late-Stage Derivatization, Supramolecular-Organocatalyst Interactions, and Nanoparticle-Enabled Functionalization Techniques
CN120365177A (zh) 一种以芳基酰胺和叔烷基卤代烷烃为原料的含季碳中心的芳基酰胺类衍生物及其制备方法
Lewis et al. The diastereoselective Meth-Cohn epoxidation of camphor-derived vinyl sulfones
HK40035593B (en) Synthesis of cantharidin
Sullivan The total synthesis and manipulations of norcembrenolides
Chuang Homogeneous catalysis in organic synthesis
HK40035593A (en) Synthesis of cantharidin
Ye Total Synthesis of Mycolactone E and Iriomoteolide-1b Stereoisomer via Ring-Closing Metathesis Strategies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220301